Data Insights

PLX-038 by ProLynx for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

PLX-038 is under clinical development by ProLynx and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - PLX-038 in Triple-Negative Breast Cancer (TNBC)

Data Insights

PLX-038 by ProLynx for Solid Tumor: Likelihood of Approval

PLX-038 is under clinical development by ProLynx and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - PLX-038 in Solid Tumor

Data Insights

PLX-038 by ProLynx for Recurrent Medulloblastoma: Likelihood of Approval

PLX-038 is under clinical development by ProLynx and currently in Phase II for Recurrent Medulloblastoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - PLX-038 in Recurrent Medulloblastoma

Data Insights

PLX-038 by ProLynx for Ependymoma: Likelihood of Approval

PLX-038 is under clinical development by ProLynx and currently in Phase II for Ependymoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - PLX-038 in Ependymoma

Data Insights

PLX-038 by ProLynx for Paraplegia: Likelihood of Approval

PLX-038 is under clinical development by ProLynx and currently in Phase II for Paraplegia. According to GlobalData, Phase II drugs...

Data Insights

PLX-038 by ProLynx for Central Nervous System (CNS) Tumor: Likelihood of Approval

PLX-038 is under clinical development by ProLynx and currently in Phase II for Central Nervous System (CNS) Tumor. According to...